DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell Lymphoma
Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Poor prognosis dufuse large B-cell lymphoma (DLBCL) represents 50% of all DLBCL with overall
cure rates ranging from 50-60% with modern dose-dense immunochemotherapy regimens such as
R-CHOP14. Using an alternative strategy, as infusional and dose-adjusted R-EPOCH, the
investigators have shown an 83% of complete responses (CR), with an estimated 5-year overall
survival (OS) rate of 75% (García-Suárez et al. British Journal of Haematology 2007,
136:276). Despite this improvement in outcome, the search for new treatment strategies should
continue. Therefore, compared with prior R-EPOCH the investigators decided to investigate
whether the introduction of dexamethasone (40 mg IV on days 1-5) in place of prednisone
(based upon data which demonstrated that the former was associated with enhanced Central
Nervious System penetration) and the reduction of treatment intervals from 3 to 2 weeks would
be feasible and might improve the outcome in this group of patients.